POS1089 ASSOCIATION BETWEEN PAIN SEVERITY AND HEALTHCARE UTILIZATION IN AN OSTEOARTHRITIS POPULATION: AN 18-YEAR RETROSPECTIVE COHORT STUDY

Background: Osteoarthritis (OA) is a common disease that varies in severity among patients. A standardized definition to classify patients into different levels lacking, however, due the disease’s complex pathogenesis and presentation. Prior studies have shown associations between pain higher healthcare resource utilization (HRU) costs. We investigated an association by examining use of specific OA-related treatments across intensity large, integrated health system’s OA population over 18-year period. Objectives: Our aim was compare medications other experiencing mild, moderate, or severe pain. Methods: This retrospective study electronic records from 2001 2018 at Geisinger, system Pennsylvania. Patients were included with diagnosis code for (ICD-9: 715.*, ICD-10 M15-19) on problem list encounter OA-specific procedure (hip knee replacement, arthroscopy injection). examined scores (0-10 scale, 10 being worst pain) taken after first date defined episodes starting score’s lasting 90 days. If new score measured before days elapsed, episode extended additional days, this process repeated as necessary. Each categorized mild (pain 0-3), moderate (4-6), (7-10) based initial score, could contribute multiple analysis. Descriptive statistics used quantify treatment during each patients’ episodes. Percentages who had any medication types (tramadol, non-tramadol opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), injectable corticosteroids, acetaminophen, salicylates, duloxetine, homeopathic medications, topical over-the-counter (OTC) compared types. hip surgeries, spine joint imaging procedures (x-ray, computed tomography magnetic resonance) consults care management, orthopedics physical medicine rehabilitation) also compared. All analyses logistic regression p-values <0.05 considered significant. Results: identified 290,897 OA, representing 34% 2018; 58% female mean age 49 years BMI 30.5 kg/m2. total 801,144 defined, 75% having least one score. The two most frequently occurring 0 (17%) 5 (13%), classified 43% 32% 25% severe. Significantly percentages certain (NSAIDs, opioid, duloxetine) both episodes, but less likely be increased (acetaminophen, OTC medications). Knee imaging, specialists all consistently significantly more occur versus (relative risk ratios 1.76, 1.25 1.35 vs respectively, 2.00, 1.44 1.46 <0.05). Conclusion: While generally recognized subjective measure influenced unmeasured factors can confounded effectiveness, it nevertheless primary symptom OA. It important understand relationship utilization, our results support overall provide details extent which depends type. Acknowledgements: Pfizer Eli Lilly Company sponsoring study. Disclosure Interests: Jove Graham Grant/research from: I am employee Geisinger received financial connection development abstract, Tonia Novosat Haiyan Sun Brian Piper Joseph Boscarino Vanessa Duboski Melissa Kern Eric Wright Rebecca Robinson Shareholder of: & Co., Employee Edward Casey Pfizer, Inc., Paid instructor for: As Inc. part my role., Craig Beck Jerry Hall Patricia Schepman